Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Plenary Session

Plenary Session artwork

Cornell, Calley Means, and Lp (a)

Nov 15, 20269 minAudio

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drvinayprasad.com/subscribe

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

SPEAKER_00The University Press Office, Cali Means' Explosive Revelations, and Lipoprotein Little A, I've got a lot in store for you this week. Well, I saw something funny recently on LinkedIn. I saw that the Cornell University Press Office proudly announces that for the very first time in Cornell history, Cornell has achieved the greatest benchmark, the high-water mark, of eight people in Congress, the most number of Cornell grads ever to be in Congress. And I know the University Press Office thinks this is a big win, but is it really?

SPEAKER_00Congress is the single institution in America that's most despised by Americans. That's because the people who go to Congress, they claim they're there to do good for the American people, but they're really there to do well for themselves. They don't accomplish anything of value, and we've seen that over and over again. And yet Cornell is very proud of the fact that they finally got eight people there. Well, the press office I have a lot of problems with over the years, and this is the latest example. And I want to know if they really think that by highlighting this they can distract from the real reason Cornell's been in the news the last few months, which is, yes,

SPEAKER_00the potential sexual assault and the fact there's a vote of no confidence against the president and all that stuff that's keeping Cornell in the headlines over and over again. You think you're going to get away from that headline by proudly touting that you got eight people in Congress? I don't think so. I think you're wedded to that headline until you really do something about it. Every year that the Nobel Prize is awarded, I see universities, they bend over backwards to see if someone ever was at their university. So even though there's a professor of physics at Berkeley who's worked there for 20 years, they say, actually, he did a postdoc at University of Chicago, too.

SPEAKER_00So University of Chicago now has 142 people who are Nobel laureates associated with the university. And MIT says, actually, he did an undergraduate here too. So we got 110 people associated with MIT. And Harvard says, he actually used the toilet here once. So he's associated with us too. And everyone's bending over backwards to see who's associated with them. It's so ridiculous. Nobody cares. They probably care about the place they were at when they had the discovery that led to the Nobel Prize, that might be of interest. The kind of circumstances that allowed someone the creativity and freedom to do that, that might be of interest.

SPEAKER_00But the fact that they were once at your institution at some point in their career means nothing, should mean nothing. But the University Press Office loves that. Every year, there are medical stories that the University Press Office offers us. They say, Researchers have a new cure for Alzheimer's, potential path, potential breakthrough for Alzheimer's. Almost all of these press releases are total fluff. They exaggerate to the point of lying about the research that has been done. At times, the researchers may be uncomfortable with the press releases that are being put out by the university.

SPEAKER_00I don't understand why universities hire a group of people with communications background to do this work. Universities are full of people who are well-suited to communicate science. They're the people who are at the university. If I was at a university like Cornell, I would have a contest for all of the students to say who can make the best five-minute video enticing applicants to come to Cornell. And then I'd post them on YouTube, see whichever gets the most upvotes, likes, And comments, which, by the way, you should be doing right now on this video.

SPEAKER_00Whoever gets the most, it's a winner of the prize. You know, and universities should take advantage of the people already there and realize that the audience, the American people, are much more willing to tolerate nuance and ambiguity and accuracy in their science coverage. So I personally don't care that they got eight people in Congress. Woo hoo. Good for you, Cornell. Good luck getting out of the other fiasco you find yourself in. Cali memes. I'm a little bit biased because Callie Means is a friend of mine and throughout my time in Washington I frequently talked to Callie and Callie was

SPEAKER_00a source of inspiration and somebody who I consider a friend and a professional colleague and we're very much like-minded. If you have to put my views in a camp, you would probably put me in the Maha camp. And I think there's been a lot of uproar in the Maha community, as Callie talks about ways in which we in the Maha movement, and that has to do with better food for kids, less pesticides and pollutants in our agriculture, and better drug and device safety studies and better efficacy studies. This is all part of the Maha movement. We don't want corporate capture.

SPEAKER_00We want what's best for the American people. And when we went to Washington, there were headwinds in our face. And Callie talks about some of those headwinds on the Joe Rogan podcast and with CBS, Face the Nation with Margaret Brennan. And a lot of it rings true to me. The things that I had personal firsthand knowledge of ring true to me. And the things I wasn't there for, I can't speak to. I wasn't there for that. I do think that there's a powerful vested interest in not defining and eliminating ultra-processed foods from children's diets.

SPEAKER_00I think there's a powerful interest in making sure kids' lunches at school continue to remain garbage. I think there's powerful interests that don't want appropriate randomized controlled trials powered for the appropriate endpoints for vaccines or devices or drugs. And those powerful forces have ways in which they can use the money to exert pressure on any administration. You know, I'm eager to see what Kelly does with this energy and I'm eager to see where Maha goes. I think Maha is a political movement that is a bit flexible.

SPEAKER_00It can move where the people want it to move. And I think it's something that has broad popular support. It is bipartisan in a way. It's sort of that horseshoe theory of politics is where the left meets the right because it's things that make sense. They have common sense for a lot of people. And so I'm going to be following along and staying tuned on this topic. Lipoprotein little a. You know, for years, lipoprotein little a was something that everyone said is going to be the holy grail. It's not enough that you control your LDL. You've got to get your lipoprotein little a down.

SPEAKER_00How high is your lipoprotein little a? You better test it. Well, we finally have the results of the Horizon trial. This is Novartis' big study of an antisense oligonucleotide, and it lowers lipoprotein little a. There's no question about it. It dramatically lowers LP little a. It even has a little spillover effect on LDL. It lowers that as well. And they took individuals at high risk of cardiovascular disease and they randomized the drug or not. And they measured major adverse cardiovascular events, a composite of four endpoints. And lo and behold, the curves were completely superimposable.

SPEAKER_00Absolutely no benefit at all in terms of any cardiovascular outcomes from taking the LP little a drug made by Novartis in the Horizon study versus not taking placebo control on the backdrop of statin therapy. Now, when they gave the top line results, many of us were waiting for a particular thing. We wanted to look at the subgroup analysis. Now, you should always be careful how you interpret subgroups and just because it works in a subgroup and doesn't work in the overall trial doesn't mean you should use it

SPEAKER_00in And one thing you might see is that although the LP inclusion criteria was 90 and above in the study, what if you started to see that the curve separated a little bit? If you were over 200 or 194, something higher, a higher number, maybe there'd be some signal there. It's not statistically significant, but the reason seeing that signal would be important is it would directly inform ongoing studies by Lilly on siRNA and another company on siRNA.

SPEAKER_00They're other competitors. SiRNA drugs seem to lower LP a little bit more Some of these trials are run in people whose baseline LP little a is higher. So it's possible that even though Horizon is negative, those would be positive. And you could look in Horizon and in the subgroup of people with high baseline LP little a, if it started to trend towards benefit in that subgroup, you might have more pretest probability that the subsequent drugs will work. Well, when I got the manuscript, I dug, dug, dug, I found that subgroup and boy,

SPEAKER_00Stone cold negative. It actually didn't work at all at any baseline LP at all. There was likely a spurious post hoc finding of it. Looked like it was trending towards benefit in higher systolic blood pressure. I don't put much stock in that. If you look at enough subgroups, some by chance alone will be positive. After all, that is what that p-value is. You know, look at 20 subgroups, you're going to get some positivity. So what am I to take of this? I would say that it's a great cautionary tale. That surrogate endpoints aren't destiny and you can improve an LP little

SPEAKER_00a and not improve the outcome. I think that maybe it's too little too late. Maybe getting all the way to 60 with that LP little a high for most of your life, it's too little too late to fix it when you're 60. Maybe you needed to get them earlier, but that's a hypothesis that needs to be tested. And I certainly think there's just no hint that even at high baseline LP little a treating them at this point, even with a market reduction, LP little a will have a benefit. So I would be pessimistic about those ongoing studies which are slated to report out in 2028 and 2031. I would be pessimistic, but we'll see what others think.

SPEAKER_00And I think it's a good reminder that although we can be critical of cardiovascular disease because there have been missteps, cardiovascular disease trialists are still committed to randomized trials that measure clinical endpoints. And that is important. And we haven't gotten past that. We're still in that business. Those are my thoughts. If you like this video, you know what to do. Like, subscribe, comment, leave a message below. Drive that traffic and I'll be back with more videos and more VPZD shows. The next one I think will be on ZDogg's channel. So check it out there. Until next time.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. New AML vax, MAHA, and Listener Questions

    Nov 20, 202647 minAudio

    Live episode from Youtube This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drvinayprasad.com/subscribe

    Credit the people on this episode

  2. Will cancer be cured in 10 years?

    Nov 18, 20267 minAudio

    This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drvinayprasad.com/subscribe

    Credit the people on this episode

  3. Elizabeth Holmes/ AI researchers start smoking/ Moderna vax

    Oct 25, 202621 minAudio

    Elizabeth Holmes/ AI researchers start smoking/ Moderna vax by Plenary Session This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit...

    Credit the people on this episode

  4. Pope has cancer; Phase 1 trials for AI; Can AI hack cancer trials__1

    Oct 17, 202622 minAudio

    Pope has cancer; Phase 1 trials for AI; Can AI hack cancer trials__1 by Plenary Session This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit...

    Credit the people on this episode

  5. An interview with Dr. Vinay Prasad

    Oct 8, 20261 hr 9 minAudio

    This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drvinayprasad.com/subscribe

    Credit the people on this episode